NASDAQ:OXFD - Oxford Immunotec Global Stock Price, Forecast & News

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

Oxford Immunotec Global PLC (NASDAQ:OXFD) announced its quarterly earnings data on Tuesday, November, 5th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.09. The company had revenue of $21.20 million for the quarter, compared to analysts' expectations of $20.23 million. Oxford Immunotec Global had a net margin of 199.21% and a return on equity of 15.77%. Oxford Immunotec Global's revenue was up 31.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.13) EPS. View Oxford Immunotec Global's Earnings History.

Oxford Immunotec Global is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Oxford Immunotec Global.

2 analysts have issued 12-month price targets for Oxford Immunotec Global's stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate Oxford Immunotec Global's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 22.5% from the stock's current price. View Analyst Price Targets for Oxford Immunotec Global.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford Immunotec Global.

News articles about OXFD stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oxford Immunotec Global earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Oxford Immunotec Global.

Oxford Immunotec Global saw a drop in short interest in the month of January. As of January 15th, there was short interest totalling 411,000 shares, a drop of 9.6% from the December 31st total of 454,700 shares. Based on an average trading volume of 113,100 shares, the short-interest ratio is presently 3.6 days. Currently, 1.6% of the shares of the company are short sold. View Oxford Immunotec Global's Current Options Chain.

Some companies that are related to Oxford Immunotec Global include Heska (HSKA), Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Arca Biopharma (ABIO), GeneNews (GNWSF), Achieve Life Sciences (ACHV) and Akers Biosciences (AKER).

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include AbbVie (ABBV), Immunomedics (IMMU), Halozyme Therapeutics (HALO), Intel (INTC), Sangamo Therapeutics (SGMO), Gold Resource (GORO), Adaptimmune Therapeutics (ADAP), Akorn (AKRX), Aptose Biosciences (APTO) and Fate Therapeutics (FATE).

Oxford Immunotec Global's stock is owned by many different of retail and institutional investors. Top institutional shareholders include California Public Employees Retirement System (0.19%) and Campbell & CO Investment Adviser LLC (0.14%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.

OXFD stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Oxford Immunotec Global.

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OXFD stock can currently be purchased for approximately $16.32.

Oxford Immunotec Global has a market capitalization of $431.62 million and generates $59.75 million in revenue each year. The company earns $120.78 million in net income (profit) each year or $0.51 on an earnings per share basis. Oxford Immunotec Global employs 215 workers across the globe.View Additional Information About Oxford Immunotec Global.

The official website for Oxford Immunotec Global is http://www.oxfordimmunotec.com/.

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]